BCKDHB

BCKDHB encodes the E1β subunit of the mitochondrial branched-chain α-ketoacid dehydrogenase (BCKDH) complex, which catalyzes the oxidative decarboxylation of branched-chain α-ketoacids derived from leucine, isoleucine, and valine. BCKDHB must be co-expressed with its partner subunit BCKDHA (E1α) for holoenzyme assembly and catalytic activity, and residues R170 and Q346 within E1β are critical for stable β-β' subunit interaction at the K⁺ ion-binding loop and subunit interface (PMID:40009698, PMID:22326532). Loss-of-function mutations in BCKDHB cause maple syrup urine disease (MSUD), and AAV-mediated restoration of BCKDHB expression rescues perinatal lethality and normalizes MSUD biomarkers in knockout mice, confirming that E1β reconstitution is sufficient to restore complex activity in vivo (PMID:36880392, PMID:40009698).

1. 1991 High

   Establishing the chromosomal position of BCKDHB at 6p21-22 provided the genomic framework needed to link clinical MSUD mutations to this locus.

   Evidence Somatic cell hybrid analysis and in situ hybridization

   PMID:1889817

   Open questions at the time

   • No functional characterization of the gene product was performed
   • No disease-causing mutations at this locus had yet been mapped
2. 2012 Low

   Molecular modeling of MSUD-associated missense mutations R170H and Q346R revealed that these E1β residues are critical for β-β' subunit assembly by stabilizing the K⁺ ion-binding loop and interface contacts, providing the first residue-level structural rationale for E1β dysfunction.

   Evidence In silico molecular modeling of missense mutations combined with clinical and biochemical characterization

   PMID:22326532

   Open questions at the time

   • Structural predictions were not validated by mutagenesis or biophysical experiments
   • No crystal structure or cryo-EM data for the mutant complexes
   • Functional impact on enzyme kinetics was inferred, not directly measured
3. 2018 High

   Identification of a whole-gene BCKDHB deletion mediated by Alu-Alu recombination established a structural mutational mechanism for complete BCKDHB loss, broadening the known mutational spectrum of MSUD.

   Evidence Next-generation sequencing, array CGH, and breakpoint sequencing in an MSUD patient

   PMID:29740478

   Open questions at the time

   • Frequency of Alu-mediated deletions among MSUD patients is unknown
   • No functional rescue was attempted to confirm pathogenicity of the deletion alone
4. 2023 High

   AAV8-mediated neonatal delivery of BCKDHB rescued lethality and normalized branched-chain amino acid levels in Bckdhb-knockout mice, directly demonstrating that E1β replacement is sufficient to restore BCKDH complex activity in vivo.

   Evidence AAV8-EF1α-BCKDHB gene therapy in Bckdhb−/− mice with biochemical assay of MSUD biomarkers

   PMID:36880392

   Open questions at the time

   • Long-term durability and tissue-specific requirements of gene therapy were not fully defined
   • Whether liver-restricted expression alone is sufficient was not resolved
5. 2025 High

   A dual-gene AAV9 vector co-expressing BCKDHA and BCKDHB reconstituted holoenzyme activity in vitro and rescued both Bckdha and Bckdhb knockout mice and a MSUD calf, establishing that obligate co-expression of both E1 subunits is required for holoenzyme assembly.

   Evidence Dual-gene rAAV9 reconstitution in HEK293T cells and in vivo rescue across two mouse knockout models and a bovine MSUD model

   PMID:40009698

   Open questions at the time

   • Stoichiometric requirements between E1α and E1β for optimal assembly are not defined
   • Whether dual-vector approach achieves therapeutic levels in human tissues remains untested

• The structural basis of E1β contributions to BCKDH holoenzyme assembly and catalysis—including experimental validation of proposed critical residues and the K⁺ ion-binding loop—remains unresolved at atomic resolution.
• No experimentally determined structure of human E1β mutant complexes exists
• Tissue-specific regulation of BCKDHB expression and its contribution to metabolic flux is poorly characterized
• Mechanism by which E1β loss selectively impairs complex assembly versus catalytic activity is unclear